Pentwater Capital Management Adds $572M in Masimo Corporation ($MASI)

Key Points

  • Wall Street's consensus rating on $MASI is Hold and an average price target of $180.
  • $MASI last traded around $179.95.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Pentwater Capital Management acquired a new position in Masimo Corporation ($MASI), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,176,000 shares of Masimo Corporation. Pentwater Capital Management's holdings in Masimo Corporation were worth $571.52 million as of its most recent filing.

Masimo Corporation Stock Price

Shares of Masimo Corporation ($MASI) traded around $179.95 on Sunday.

Last price$179.95
Market cap$9.42B
P/E ratio44.43
Forward P/E26.87
PEG ratio4.83
Beta1.10
52-week low$125.94
52-week high$179.99
50-day MA$178.69
200-day MA$156.66
Current ratio2.67
Quick ratio1.27
Debt-to-equity0.62

Masimo Corporation Earnings

EPS (ttm)$4.05
Revenue (ttm)$1.56B
Revenue growth8.50%
Net margin4.90%
Return on equity24.99%
Next earningsAug 4, 2026

Analysts Set New Price Targets

ConsensusHold
Average target$180
High target$180
Low target$180
Analysts covering3

About Masimo Corporation

Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

ExchangeNGM
SectorHealthcare
IndustryMedical Devices
HeadquartersIrvine, CA
CEOMs. Catherine M. Szyman
Employees2,200

Get Masimo Corporation alerts

New 13F filings, insider trades, and analyst moves on $MASI, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.